#75 - David Light: Zantac recall due to cancer concerns – what you need to know

1:37:30
 
Share
 

Manage episode 244350869 series 2352826
By Peter Attia, MD, Peter Attia, and MD. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

In this episode, David Light, CEO of Valisure (the company which alerted the FDA to the Zantac cancer concerns), explains the story behind the recent recalls by manufacturers of ranitidine, a common heartburn medication, sold under the trade name Zantac, due to a potential link to increased cancer risk. David breaks down all the evidence, the role of his unique pharmacy company which tests all its drugs before being dispensed to consumers, and the reason behind the FDA’s tempered reaction to the alarming study results. David makes the argument that Zantac/ranitidine is an inherently unstable molecule which explains the grossly excessive amounts of NDMA (a probable human carcinogen) as opposed to just a contamination for which there could be numerous causes. Finally, David and Peter both provide recommendations for what to do if you or someone you know is currently taking Zantac/ranitidine.

We discuss:

  • The impetus for starting Valisure, a unique online pharmacy that tests all its medications [6:45];
  • The story behind the recall of valsartan, and the role which Valisure played [24:30];
  • Testing Zantac: The shocking results from Valisure’s initial testing with major potential cancer implications [36:00];
  • NDMA - the probable human carcinogen found in Zantac/ranitidine [48:45];
  • The epidemiology question: Are we inferring too much from epidemiology? What can we take away from the existing studies? [53:30];
  • The staggering results from the 2016 Stanford study, why it didn’t alarm more people, and how Valisure found the missing biological link [1:01:30];
  • Alerting the FDA, the FDA’s tempered response, and question of contamination vs. inherent instability [1:07:30];
  • How confident is David that the elevated levels of NDMA being found in ranitidine are not due to instrumentation, human error, or temperature contamination? [1:24:15];
  • The massive risk being taken by the FDA by not doing more to keep ranitidine away from consumers [1:25:15];
  • If someone is taking Zantac/ranitidine, what should they do? What else do they need to know? [1:27:45]; and
  • More.

Learn more: https://peterattiamd.com/ Show notes page for this episode: https://peterattiamd.com/davidlight/ Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/ Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/ Connect with Peter on Facebook | Twitter | Instagram.

97 episodes